Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials
暂无分享,去创建一个
P. Sandercock | J. Grotta | M. Kaste | W. Hacke | G. Donnan | J. Wardlaw | J. Emberson | C. Baigent | M. Lansberg | G. Howard | L. Blackwell | S. Davis | G. Murray | K. Lees | R. Lindley | R. von Kummer | E. Bluhmki | D. Toni | P. Lyden | K. Toyoda | W. Whiteley | S. Davis
[1] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[2] M. Kaste,et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.
[3] D K Owens,et al. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. , 1996, Archives of internal medicine.
[4] P Trouillas,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. , 1998, Lancet.
[5] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[6] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.
[7] H. Diener,et al. Association Between Disability Measures and Healthcare Costs After Initial Treatment for Acute Stroke , 2007, Stroke.
[8] Gary A. Ford,et al. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.
[9] M. Kaste,et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.
[10] Keith Muir,et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.
[11] Jeffrey L Saver,et al. Quantifying the Value of Stroke Disability Outcomes: WHO Global Burden of Disease Project Disability Weights for Each Level of the Modified Rankin Scale , 2009, Stroke.
[12] Gregory W Albers,et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.
[13] J. Saver,et al. Statistical Analysis of the Primary Outcome in Acute Stroke Trials , 2012, Stroke.
[14] Werner Hacke,et al. Contemporary Outcome Measures in Acute Stroke Research: Choice of Primary Outcome Measure , 2012, Stroke.
[15] Geoff Cohen,et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.
[16] V. Howard,et al. A Simple, Assumption-Free, and Clinically Interpretable Approach for Analysis of Modified Rankin Outcomes , 2012, Stroke.
[17] P. Sandercock,et al. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis , 2013, International Journal of Stroke.
[18] K. Lees,et al. Effect Size Measures and Their Relationships in Stroke Studies , 2014, Stroke.
[19] P. Sandercock,et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .
[20] P. Sandercock,et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis , 2016, The Lancet Neurology.